As a result of this decision, the FDA is no longer enjoined from approving subsequent abbreviated new drug applications. Teva intends to seek a stay of this decision pending further appeals.
As a result of this decision, the FDA is no longer enjoined from approving subsequent abbreviated new drug applications. Teva intends to seek a stay of this decision pending further appeals.